SciELO - Scientific Electronic Library Online

vol.17 issue2Management of sports overuse injuries of the lower limb: an evidence-based review of the literatureOrthopaedic implications of physeal arrest following meningococcal septicaemia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links

  • On index processCited by Google
  • On index processSimilars in Google


SA Orthopaedic Journal

On-line version ISSN 2309-8309
Print version ISSN 1681-150X


GEURTS, J et al. Contemporary treatment of chronic osteomyelitis: implementation in low- and middle-income countries. SA orthop. j. [online]. 2018, vol.17, n.2, pp.40-43. ISSN 2309-8309.

AIM: Chronic osteomyelitis is still a difficult problem to treat in the developed world, but even more so in low- and middle-income countries. Contemporary treatment options result in satisfying outcomes in a setting with abundant resources, but the question is whether these treatment options can be translated to other, less supported health care systems and if they obtain the same results. METHODS: Eighteen patients with established chronic osteomyelitis (eight type III, ten type IV) were prospectively enrolled and treated in a one-stage procedure with radical debridement and dead space management using bioactive glass S53P4 granules, together with adjuvant antibiotic therapy. RESULTS: Thirteen patients were assessed at 24 months. Infection control was achieved in Ave patients (38%). Eight patients (61.5%) had persistence or recurrence of infection. Loss to follow-up was substantial (Ave patients, 28%). CONCLUSION: Due to specific challenges treating chronic osteomyelitis in low- and middle-income countries, contemporary treatment options cannot be 'copy-pasted' with the same results in these settings. LEVEL OF EVIDENCE: Level 4.

Keywords : osteomyelitis; bio-active glass; biomaterial; low and middle-income countries.

        · text in English     · English ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License